Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD

This article was originally published in The Tan Sheet

Executive Summary

Novartis has halted use of claim that Rx Transderm Scop patch is "clinically proven more effective than Dramamine," CBBB division says in recent Case Report. Pharmacia brought the issue to NAD's attention, which recommended Novartis remove superiority claims from ads and provide a drowsiness disclaimer (1"The Tan Sheet" Nov. 13, 2000, p. 11). Following Novartis' unsuccessful appeal to NARB, NAD concludes firm has "made a good faith effort to comply" with advertising division's recommendations "in both its print advertising and redesigned Web site"...

You may also be interested in...



Novartis Transderm Scop Comparative Claims With Dramamine Denied By NAD

DTC ad claims for Novartis' Rx Transderm Scop declaring superiority to Pharmacia's OTC motion sickness remedy Dramamine are inappropriate due to "very significant differences" between the scopolamine patch's consumer-targeted claims and original FDA-reviewed statements, NAD states Nov. 8.

Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation

Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

Topics

UsernamePublicRestriction

Register

PS093235

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel